Tumor-specific T-bodies: Towards clinical application

Cancer Immunology Immunotherapy

Volumn 45, Issue 3-4, 1997, Pages 131-136

  Eshhar, Zelig ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Tumor specific T bodies

Indexed keywords

CANCER ANTIBODY; CHIMERIC ANTIBODY;

ANTIBODY AFFINITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MODEL; CLINICAL RESEARCH; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG RESEARCH; EFFECTOR CELL; EXPERIMENTAL MODEL; HELPER CELL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, NEOPLASM; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY REACTIONS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY, ADOPTIVE; IMMUNOTOXINS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; TRINITROBENZENES;

EID: 0030728073     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050415     Document Type: Article

References (34)

1. Alvarez-Vallina L, and Hawkins RE (1996) Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol 26: 2304-2309
2. Bach N, Waks T. Eshhar Z (1995) Specific lysis of tumor cells by a natural-killer-like cell line transfected with chimeric receptor genes. Tumor Targetting 1:203-209
3. Becker MLB, Near R. Mudgett-Hunter M, Margolies MN, Kubo RT, Kaye J, Hedrick SM (1989) Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice. Cell 58: 911-921
4. Beverly B, Kang SM, Lenardo MJ, Schwartz RH (1992) Reversal of in vitro clonal anergy by 1L-2 stimulation. Int Immunol 4:661-671
5. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee S-M, Lee T, Pope SH, Riordan GS, Whitlow M (1988). Single chain antigen binding proteins. Science 242:423-426.
6. Brocker T, Karjalainen K (1995) Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med 181:1653-1659
7. Butcher EC, Picker LJ (11996) Lymphocyte homing and homeostasis. Science 272:60-66
8. Eshhar Z, Waks T. Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90:720-724
9. Eshhar Z, Gross G, Waks T, Lustgarten J, Bach N, Ratner A, Treisman J. Schindler DG (1995) T-bodies: chimeric, T-cell receptors with antibody-type specificity. Methods companion to methods Enzymol 8:133-142
10. Finer MH, Dull TJ, Qin L, Farson D, Roberts MR (1994) kat: a high-efficiency retroviraltransduction systemfor primary human T lymphocytes. Blood 83:43-50
11. Fitzer-Attas CJ, Schindler DG, Waks T, Eshhar Z (1997) Direct T cell activation by chimeric single chain-Fv-Syk promotes Syk-Cbl association and Cbl phosphorylation. J Biol Chem 272:8551-8557
12. Fitzer-Attas CJ, Schindler DG, Waks T, Eshhar Z (1997) Harnessing Syk-family tyrosine kinases as signaling domains for chimeric scFv receptors: optimal design for T cell activation. Immunology (in press)
13. Goverman J, Gomez SM, Segesman KD, Hunkapiller T, Laug WE, Hood L (1990) Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation. Cell 60:929-939
14. Gross G, Eshhar Z (1992) Endowing T cells with antibody specificity using chimeric T cell receptors. FASEB J 6:3370-3378
15. Gross G, Gorochov G, Waks T, Eshhar Z (1989) Generation of effector T cells expressing chimeric T cell receptors with antibody type specificity. Trans Proc 21:127-130
16. Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin/T cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86: 10024-10028.
17. Gross G, Levy S, Levy R, Waks T, Eshhar Z (1995) Chimeric T cell receptors specific to a B lymphoma idiotype: A model for tumor immunotherapy. Biochem Soc Trans 23:1079-1082.
18. Huston JS, Levinson D, Mudget-Hunter M, Tai M-S, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, Oppermann H (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85:5879-5884
19. Hwu P, Shafer GE, Treisman J, Schindler DG, Gross G, Cowhead R, Rosenberg SA, Eshhar Z (1993) Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor g chain. J Exp Med 178:361-366
20. Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA. (1995) In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55:3369-3373
21. Jain RK (1994) Barriers to drug delivery in solid tumors. Sci Am 271:42-49
22. Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, Nagase F, Kurosawa Y (1987) Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 149:960-968
23. Lustgarten J, Eshhar Z (1995) Specific elimination of IgE production using T cell lines expressing chimeric T cell receptor genes. Eur J Immunol 25:2985-2991
24. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice Science 258:1795-1798
25. Moritz D, Groner B (1995) A spacer region between the single chain antibody and the CD3 ζ chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther 2:539-546
26. Moritz D, Wels W, Mattern J, Groner B (1994) Cytotoxic T lymphocytes with a grafted recognition specificity for ErbB-2-expressing tumor cells. Proc. Natl Acad Sci USA 91: 4318-4322
27. Mueller DL, Jenkins MK, Schwartz RH (1989) Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 7:445-480
28. Riethmuller G (1993) Monoclonal antibodies in cancer therapy. Curr Opin Immunol 5:732-739
29. Shaw SA, Dustin ML (1997) Making the T cell receptor go the distance: a topological view of T cell activation. Immunity 6: 361-369
30. Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z (1993) Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 151: 6577-6582
31. Tran A-C, Zhang D, Byrn R, Roberts MR (1995) Chimeric ζ-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes. J Immunol 155:1001-1009
32. Valitutti S, Lanzavecchia A (1997) Serial triggering of TCRs: a basis for the sensitivity and specificity of antigen recognition. Immunol Today 18:299-304
33. Wang Q, Finer MH (1996) Second-generation adenovirus vectors. Nat Med 2:714-716
34. Zier K, Gansbacher B, Salvadori S (1996) Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol Today 17:39-45